Human Immunology News 6.42 October 23, 2018 | |
| |
TOP STORYLILRB4 Signaling in Leukemia Cells Mediates T Cell Suppression and Tumor Infiltration Scientists used mouse models and human cells to show that LILRB4, an immunoreceptor tyrosine-based inhibition motif-containing receptor and a marker of monocytic leukemia, supports tumor cell infiltration into tissues and suppresses T cell activity via a signaling pathway that involves APOE, LILRB4, SHP-2, uPAR and ARG1 in acute myeloid leukemia cells. [Nature] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Applying modeling of associations of single cells to mass cytometry analyses of CD4+ T cells from the blood of rheumatoid arthritis (RA) patients and controls revealed a significantly expanded population of CD4+ T cells, identified as CD27− HLA-DR+ effector memory cells, in RA patients. [Sci Transl Med] Full Article In the oral cavity, human TH17 cell defects were associated with diminished periodontal inflammation and bone loss, despite increased prevalence of recurrent oral fungal infections. [Sci Transl Med] Abstract | Press Release SMAC Mimetics Induce Autophagy-Dependent Apoptosis of HIV-1-Infected Resting Memory CD4+ T Cells Scientists found that DIABLO/SMAC mimetics selectively kill HIV-memory CD4+ T cells (TCM) without increasing virus production or targeting uninfected TCM. [Cell Host Microbe] Abstract | Graphical Abstract Researchers compared monocytes from systematic lupus erythematosus (SLE) patients and matched healthy donors, and found monocytes from SLE patients exhibited more CD14+CD86+ cells, impaired phagocytic activity, and elevated interleukin (IL)-1β, IL-6, and tumor necrosis factor-α, which could be blocked by azithromycin. [Cell Death Dis] Full Article Investigators proposed to identify if airway phospholipid transfer protein (PLTP) activity can be restored by alpha-1 antitrypsin (AAT) augmentation therapy and how PLTP subdues degranulation of neutrophils in AAT deficient subjects. [Sci Rep] Full Article Inhibiting Ex Vivo Th17 Responses in Ankylosing Spondylitis by Targeting Janus Kinases The authors investigated the therapeutic potential of four different JAK inhibitors on cells derived from Ankylosing Spondylitis patients and healthy controls, cultured in vitro under T helper cell 17 (Th17)-promoting conditions. [Sci Rep] Full Article Host SAMHD1 Protein Restricts Endogenous Reverse Transcription of HIV-1 in Nondividing Macrophages Researchers demonstrated that HIV-2 produced from human primary monocyte derived macrophages displays higher endogenous reverse transcription activity than HIV-1 produced from macrophages. [Retrovirology] Full Article Using multiparametric flow cytometry, scientists examined the effect of Ty21a immunization on terminal ileum lamina propria mononuclear cells and peripheral blood CD4+ T memory subsets in volunteers undergoing routine colonoscopy. [Int Immunol] Abstract Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSThe authors provide dendritic cell (DC)-specific guidance for development of in vitro potency assays for characterization and release. They present a broad overview of in vitro potency assays suggested for DC products to determine their anti-tumor functionality. [Cytotherapy] Abstract Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
INDUSTRY NEWSThe Parker Institute for Cancer Immunotherapy and Xyphos Biosciences announced a collaboration to create universal CAR-T therapies to treat multiple cancer types using the company’s ‘convertibleCAR’® platform. [The Parker Institute for Cancer Immunotherapy] Press Release SQZ Biotechnologies announced the expansion of its collaboration with Roche in cellular therapy. The expanded partnership furthers the synergistic combination of SQZ’s innovation and expertise in cell therapy with Roche’s cancer immunotherapy expertise. [SQZ Biotechnologies] Press Release Anixa Biosciences, Inc. announced that it, along with its partner Moffitt Cancer Center, completed a pre-Investigational New Drug (IND) meeting with the FDA. [Anixa Biosciences, Inc.] Press Release The California Institute for Regenerative Medicine (CIRM) awarded City of Hope’s Xiuli Wang, Ph.D. $3.8 million to develop chimeric antigen receptor (CAR) T cells that can target and kill HIV-infected cells. The treatment will also use the cytomegalovirus vaccine to stimulate the immune system to proliferate and maintain the CAR T cells. [City of Hope] Press Release Abramson Cancer Center Receives $10.7 Million to Study CAR T Cells in Solid Tumors A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor (CAR) T cell therapy at fighting solid tumors. Specifically, the program will evaluate approaches in lung cancer and mesothelioma. [Penn Medicine] Press Release | |
| |
POLICY NEWSAzar Is Empowering Anti-fetal Tissue Research Ideologues at the Expense of Science Earlier this month, Alex Azar, secretary of the Department of Health and Human Services, visited South America, where he touted the work the United States has done to halt the spread of diseases in the region. But the same week Azar that was praising U.S.-driven health care successes abroad, he put the scientific advances of tomorrow at risk by prioritizing a far-right political ideology ahead of evidence and the health of the public. [STAT News] Editorial British Universities Set Up European Outposts as Brexit Looms Some of Britain’s leading research institutions are establishing alliances with counterparts in other European countries — a move that might allow them to keep drawing on the EU’s science funds even in the case of a ‘no-deal’ divorce from the bloc, a more extreme form that Brexit could take. [Nature News] Editorial UK’s Science Reputation ‘At Risk If Academic Visa Issues Not Resolved’ The Wellcome Trust, which grants more than £1bn for research each year, said the immigration system was “not up to scratch” after another scientific summit in the UK was marred by the visa barriers delegates and speakers faced. [The Guardian] Editorial Cancer Research to Cut Funding for Scientists Who Bully Colleagues Britain’s largest cancer charity has announced new rules to crack down on bullying and harassment. Cancer Research UK said scientists who bullied or harassed colleagues would face sanctions that could include being prevented from supervising PhD students, losing funding from the charity or being barred from applying for future grants. [The Guardian] Editorial
| |
EVENTSNEW AACR: Melanoma: From Biology to Target Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Immunology (Johns Hopkins University) NEW Tenure/Tenure Track Faculty Position – Immunology (Wayne State University) PhD Position – Antigen Presentation and Immune Regulation (Erasmus MC) Postdoctoral Fellow – Statistical Geneticist/Computational Biologist (Wellcome Sanger Institute) Postdoctoral Researcher – Autophagy and Aging (University of Oxford) Research Assistant II – Immunology (Baylor College of Medicine) Faculty Position – Immunology (Benaroya Research Institute) Faculty Position – Systems Immunology (Benaroya Research Institute) Project Leader – Immuno-Oncology (CELLECTIS Inc.) Postdoctoral Fellowship – Immunology (University of Nantes) Institute Group Leader – Lymphocyte Biology (MD Anderson Cancer Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|